Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation
View abstract on PubMed
Summary
This summary is machine-generated.Splanchnic vein thrombosis (SVT) screening is vital for liver transplant candidates. Anticoagulation therapy for SVT is safe and effective, improving recanalisation and preventing thrombosis extension.
Area Of Science
- Hepatology
- Transplantation Medicine
- Vascular Surgery
Background
- Splanchnic vein thrombosis (SVT) poses significant complications for liver transplant candidates.
- Identifying risk factors and effective treatments for SVT is crucial in this patient population.
Purpose Of The Study
- Determine the prevalence and risk factors of SVT in cirrhotic patients awaiting liver transplantation.
- Assess the efficacy and safety of anticoagulation therapy for SVT in this cohort.
Main Methods
- Systematic Doppler ultrasonography screening for thrombosis in 251 cirrhotic patients listed for transplantation.
- Comparative analysis of outcomes between patients who received anticoagulation and those who did not.
Main Results
- SVT prevalence was 8.4% at evaluation, with an additional 7.4% developing de novo thrombosis.
- Independent risk factors for SVT included low platelet count, history of variceal bleeding, and prolonged transplant waiting time.
- Anticoagulation significantly increased the rate of thrombosis recanalisation (8/19 vs. 0/10) and was associated with improved survival in patients without complete portal vein thrombosis at surgery.
Conclusions
- Systematic screening for SVT in liver transplant candidates is recommended.
- Anticoagulation therapy is safe and effective in improving recanalisation and preventing the extension of SVT.
- Early detection and management of SVT can improve outcomes for patients awaiting liver transplantation.